Adverum Biotechnologies

Adverum Biotechnologies is a clinical-stage gene therapy company based in Redwood City, California, focused on developing innovative treatments for ocular and rare diseases. Its leading product candidate, ADVM-022, is designed as a single intravitreal injection to provide long-term therapeutic effects for patients with wet age-related macular degeneration. The company's pipeline also includes ADVM-043, targeting alpha-1 antitrypsin deficiency, and ADVM-053, aimed at hereditary angioedema. Adverum collaborates with Editas Medicine to utilize its proprietary adeno-associated virus vectors for gene editing in inherited retinal diseases and has partnered with Regeneron Pharmaceuticals to develop ocular therapeutics. Founded in 2006, Adverum Biotechnologies emerged from the merger of Avalanche Biotechnologies and Annapurna Therapeutics in 2016, emphasizing its commitment to addressing chronic and debilitating conditions through advanced gene therapies.